Platelet lysate based cell therapy - Celixir

Drug Profile

Platelet lysate based cell therapy - Celixir

Alternative Names: TendoncelTM

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Celixir
  • Class Anti-inflammatories; Cell therapies
  • Mechanism of Action Angiopoietin replacements; Cell replacements; Fibroblast growth factor stimulants; Platelet derived growth factor replacements; Thrombospondin replacements; Vascular-endothelial-growth-factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tendon injuries

Most Recent Events

  • 13 Jun 2017 Celixir completes a phase II trial in Tendon injury (Tennis elbow) in Europe before June 2017 (Celixir pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top